ERBB2 and plasma cell myeloma: This strategy has successfully been applied preclinically in breast and ovarian cancer, non-Hodgkin lymphoma, and multiple myeloma using anti-HER2 (Figure 1F), anti-CD20, and anti-idiotypic (multiple myeloma) nanobodies, respectively [49,54,68].